CL2013000455A1 - Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer. - Google Patents
Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer.Info
- Publication number
- CL2013000455A1 CL2013000455A1 CL2013000455A CL2013000455A CL2013000455A1 CL 2013000455 A1 CL2013000455 A1 CL 2013000455A1 CL 2013000455 A CL2013000455 A CL 2013000455A CL 2013000455 A CL2013000455 A CL 2013000455A CL 2013000455 A1 CL2013000455 A1 CL 2013000455A1
- Authority
- CL
- Chile
- Prior art keywords
- oxadiazole
- allergic
- pulmonary
- cardiovascular
- inflammatory
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000000172 allergic effect Effects 0.000 title abstract 2
- 208000010668 atopic eczema Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract 2
- 230000003176 fibrotic effect Effects 0.000 title abstract 2
- 230000002757 inflammatory effect Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000002617 leukotrienes Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002685 pulmonary effect Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 title 1
- WKMHGUGKKDNEQH-UHFFFAOYSA-N 4-benzyloxadiazole Chemical compound C=1C=CC=CC=1CC1=CON=N1 WKMHGUGKKDNEQH-UHFFFAOYSA-N 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37392510P | 2010-08-16 | 2010-08-16 | |
| US201161492176P | 2011-06-01 | 2011-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000455A1 true CL2013000455A1 (es) | 2013-05-03 |
Family
ID=44511591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000455A CL2013000455A1 (es) | 2010-08-16 | 2013-02-14 | Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8658661B2 (enExample) |
| EP (1) | EP2606045B1 (enExample) |
| JP (1) | JP5619284B2 (enExample) |
| KR (1) | KR20130100105A (enExample) |
| CN (1) | CN103180314A (enExample) |
| AP (1) | AP2013006678A0 (enExample) |
| AR (1) | AR082696A1 (enExample) |
| AU (1) | AU2011292285A1 (enExample) |
| BR (1) | BR112013003439A2 (enExample) |
| CA (1) | CA2807364A1 (enExample) |
| CL (1) | CL2013000455A1 (enExample) |
| CO (1) | CO6680645A2 (enExample) |
| EA (1) | EA201300250A1 (enExample) |
| EC (1) | ECSP13012494A (enExample) |
| MX (1) | MX2013001872A (enExample) |
| NZ (1) | NZ605690A (enExample) |
| PE (1) | PE20130751A1 (enExample) |
| PH (1) | PH12013500301A1 (enExample) |
| SG (1) | SG187549A1 (enExample) |
| TW (1) | TW201238947A (enExample) |
| UY (1) | UY33557A (enExample) |
| WO (1) | WO2012024150A1 (enExample) |
| ZA (1) | ZA201300238B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013500301A1 (en) | 2010-08-16 | 2013-03-25 | Boehringer Ingelheim Int | Oxadiazole inhibitors of leukotriene production |
| US8580829B2 (en) * | 2010-08-26 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| JP5828188B2 (ja) * | 2010-09-23 | 2015-12-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン産生のオキサジアゾール阻害剤 |
| EA201300389A1 (ru) * | 2010-09-23 | 2013-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Оксадиазольные ингибиторы продуцирования лейкотриена |
| WO2012082817A1 (en) * | 2010-12-16 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| JP5945870B2 (ja) | 2011-03-18 | 2016-07-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カルボン酸の調製方法 |
| WO2013116182A1 (en) * | 2012-01-31 | 2013-08-08 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as inhibitors of leukotriene production |
| AR089853A1 (es) * | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
| JP6221148B2 (ja) * | 2012-02-09 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カルボキサミジン化合物の調製方法 |
| EP2746256A1 (en) | 2012-12-19 | 2014-06-25 | Basf Se | Fungicidal imidazolyl and triazolyl compounds |
| EP2746277A1 (en) | 2012-12-19 | 2014-06-25 | Basf Se | Fungicidal imidazolyl and triazolyl compounds |
| WO2014095381A1 (en) | 2012-12-19 | 2014-06-26 | Basf Se | Fungicidal imidazolyl and triazolyl compounds |
| WO2014095249A1 (en) | 2012-12-19 | 2014-06-26 | Basf Se | Fungicidal imidazolyl and triazolyl compounds |
| EP2746279A1 (en) | 2012-12-19 | 2014-06-25 | Basf Se | Fungicidal imidazolyl and triazolyl compounds |
| CN103724279B (zh) * | 2014-01-20 | 2016-04-06 | 新发药业有限公司 | 一步成环制备2-甲基-4-氨基-5-氨基甲基嘧啶的便捷合成方法 |
| WO2015140130A1 (en) * | 2014-03-17 | 2015-09-24 | Remynd Nv | Oxadiazole compounds |
| IL291418B2 (en) | 2022-03-16 | 2024-05-01 | Anima Biotech Inc | Substances that function as modulators of cMYC-mRNA translation and their uses for cancer treatment |
| JP2023140319A (ja) | 2022-03-22 | 2023-10-04 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3141019A (en) * | 1964-07-14 | Chaohj | ||
| GB1053825A (enExample) * | 1963-03-22 | |||
| JP2719742B2 (ja) * | 1991-04-30 | 1998-02-25 | 株式会社大塚製薬工場 | フェニルチアゾール誘導体 |
| WO1999002505A1 (en) * | 1997-07-10 | 1999-01-21 | Janssen Pharmaceutica N.V. | Il-5 inhibiting 6-azauracil derivatives |
| EP0987265A1 (en) * | 1998-09-18 | 2000-03-22 | Janssen Pharmaceutica N.V. | Interleukin-5 inhibiting 6-azauracil derivatives |
| JP2003506451A (ja) | 1999-08-06 | 2003-02-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | インターロイキン−５を抑制する６−アザウラシル誘導体 |
| US7319108B2 (en) | 2004-01-25 | 2008-01-15 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted heterocycles, process for their preparation and their use as medicaments |
| CN101039938A (zh) * | 2004-10-18 | 2007-09-19 | 默克公司 | 作为flap抑制剂的二苯基取代的烷烃 |
| EP2272848B1 (en) * | 2005-08-10 | 2012-12-26 | Glaxosmithkline LLC | Xanthine derivatives as selective HM74A agonists |
| GB0516464D0 (en) * | 2005-08-10 | 2005-09-14 | Smithkline Beecham Corp | Novel compounds |
| GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US20070219206A1 (en) * | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| EP2013174B1 (en) * | 2006-04-11 | 2013-05-08 | Merck Sharp & Dohme Corp. | Diaryl substituted alkanes |
| US20070287699A1 (en) * | 2006-05-01 | 2007-12-13 | Virobay, Inc. | Antiviral agents |
| US20080096900A1 (en) * | 2006-06-26 | 2008-04-24 | Amgen Inc. | Methods for treating atherosclerosis |
| US8440672B2 (en) * | 2006-09-01 | 2013-05-14 | Merck Sharp & Dohme Corp. | Diphenyl substituted alkanes |
| FR2906866A1 (fr) * | 2006-10-10 | 2008-04-11 | Felix Ifrah | Luminaire comprenant au moins un moyen d'eclairage dont l'activation s'effectue par l'emission d'un rayonnement lumineux |
| WO2008050200A1 (en) * | 2006-10-24 | 2008-05-02 | Pfizer Products Inc. | Oxadiazole compounds as calcium channel antagonists |
| WO2008128335A1 (en) | 2007-04-20 | 2008-10-30 | Merck Frosst Canada Ltd. | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2008156721A1 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Diphenyl substituted alkanes |
| US20110003815A1 (en) | 2007-10-10 | 2011-01-06 | Merck & Co., Inc. | Diphenyl substituted cycloalkanes |
| WO2010089686A1 (en) * | 2009-02-04 | 2010-08-12 | Pfizer Inc. | 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives |
| WO2011143466A1 (en) | 2010-05-12 | 2011-11-17 | Vanderbilt University | Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| PH12013500301A1 (en) | 2010-08-16 | 2013-03-25 | Boehringer Ingelheim Int | Oxadiazole inhibitors of leukotriene production |
| US8580829B2 (en) | 2010-08-26 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| JP5828188B2 (ja) | 2010-09-23 | 2015-12-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン産生のオキサジアゾール阻害剤 |
-
2011
- 2011-08-11 PH PH1/2013/500301A patent/PH12013500301A1/en unknown
- 2011-08-11 KR KR1020137003938A patent/KR20130100105A/ko not_active Withdrawn
- 2011-08-11 EA EA201300250A patent/EA201300250A1/ru unknown
- 2011-08-11 SG SG2013003694A patent/SG187549A1/en unknown
- 2011-08-11 CN CN2011800500399A patent/CN103180314A/zh active Pending
- 2011-08-11 EP EP11748842.9A patent/EP2606045B1/en active Active
- 2011-08-11 NZ NZ605690A patent/NZ605690A/en not_active IP Right Cessation
- 2011-08-11 WO PCT/US2011/047356 patent/WO2012024150A1/en not_active Ceased
- 2011-08-11 AU AU2011292285A patent/AU2011292285A1/en not_active Abandoned
- 2011-08-11 MX MX2013001872A patent/MX2013001872A/es not_active Application Discontinuation
- 2011-08-11 BR BR112013003439A patent/BR112013003439A2/pt not_active IP Right Cessation
- 2011-08-11 AP AP2013006678A patent/AP2013006678A0/xx unknown
- 2011-08-11 PE PE2013000279A patent/PE20130751A1/es not_active Application Discontinuation
- 2011-08-11 CA CA2807364A patent/CA2807364A1/en not_active Abandoned
- 2011-08-11 JP JP2013524874A patent/JP5619284B2/ja active Active
- 2011-08-12 US US13/208,582 patent/US8658661B2/en active Active
- 2011-08-15 TW TW100129127A patent/TW201238947A/zh unknown
- 2011-08-15 UY UY0001033557A patent/UY33557A/es not_active Application Discontinuation
- 2011-08-15 AR ARP110102966A patent/AR082696A1/es unknown
-
2013
- 2013-01-10 ZA ZA2013/00238A patent/ZA201300238B/en unknown
- 2013-02-14 CL CL2013000455A patent/CL2013000455A1/es unknown
- 2013-02-15 CO CO13031460A patent/CO6680645A2/es not_active Application Discontinuation
- 2013-03-15 EC ECSP13012494 patent/ECSP13012494A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2606045B1 (en) | 2016-01-06 |
| PH12013500301A1 (en) | 2013-03-25 |
| ZA201300238B (en) | 2014-06-25 |
| EP2606045A1 (en) | 2013-06-26 |
| AR082696A1 (es) | 2012-12-26 |
| EA201300250A1 (ru) | 2013-08-30 |
| US20120220561A1 (en) | 2012-08-30 |
| ECSP13012494A (es) | 2013-04-30 |
| AP2013006678A0 (en) | 2013-01-31 |
| JP5619284B2 (ja) | 2014-11-05 |
| AU2011292285A1 (en) | 2013-01-31 |
| SG187549A1 (en) | 2013-03-28 |
| WO2012024150A1 (en) | 2012-02-23 |
| NZ605690A (en) | 2014-06-27 |
| CA2807364A1 (en) | 2012-02-23 |
| TW201238947A (en) | 2012-10-01 |
| UY33557A (es) | 2012-03-30 |
| KR20130100105A (ko) | 2013-09-09 |
| CN103180314A (zh) | 2013-06-26 |
| MX2013001872A (es) | 2013-09-02 |
| BR112013003439A2 (pt) | 2019-09-24 |
| PE20130751A1 (es) | 2013-06-21 |
| CO6680645A2 (es) | 2013-05-31 |
| US8658661B2 (en) | 2014-02-25 |
| JP2013534245A (ja) | 2013-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013000455A1 (es) | Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer. | |
| LTC3057969I2 (lt) | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit | |
| EA201400729A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ СОДЕРЖАТ ГЛИТАЗОНЫ И Nrf2 АКТИВАТОРЫ | |
| CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
| JO3366B1 (ar) | مثبطات بيرازوليل كوينوكزالين كاينيز | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| GT201400147A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
| MX377340B (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| CL2017002283A1 (es) | Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014) | |
| UA108101C2 (xx) | Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| BR112017009648A2 (pt) | composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto. | |
| EA201491215A1 (ru) | Несиалированные противовоспалительные полипептиды | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| CL2011003229A1 (es) | Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer. | |
| CL2016002877A1 (es) | Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos. | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| MX386935B (es) | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
| EA201591004A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EA201270254A1 (ru) | Производные 5-фторпиримидинона | |
| EA201270257A1 (ru) | Производные n1-сульфонил-5-фторпиримидинона | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| EA201500801A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
| EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ |